{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:16:10Z","timestamp":1778854570966,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jtocrr.2022.100353","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T13:12:13Z","timestamp":1654693933000},"page":"100353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-1838","authenticated-orcid":false,"given":"Kenji","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-281X","authenticated-orcid":false,"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Shiotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Date","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyo","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Hiranuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hibiki","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshie","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Iwasaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsaku","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2022.100353_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtocrr.2022.100353_bib2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jjco\/hyn072","article-title":"Trends in lung cancer incidence by histological type in Osaka, Japan","volume":"38","author":"Toyoda","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2022.100353_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","article-title":"Current standards for clinical management of small cell lung cancer","volume":"7","author":"Farago","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtocrr.2022.100353_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4065\/83.3.355","article-title":"Small cell lung cancer","volume":"83","author":"Sher","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtocrr.2022.100353_bib5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"KEYNOTE-189 investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100353_bib6","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100353_bib7","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100353_bib8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2022.100353_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lungcan.2021.08.015","article-title":"Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer","volume":"161","author":"Morimoto","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2022.100353_bib10","article-title":"A\u00a0real-world study on the effectiveness and safety of pembrolizumab plus chemotherapy for nonsquamous NSCLC","volume":"3","author":"Fujimoto","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2022.100353_bib11","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1016\/j.cllc.2020.04.006","article-title":"The role of performance status in small-cell lung cancer in the era of immune checkpoint inhibitors","volume":"21","author":"Friedlaender","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2022.100353_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12885-016-2222-4","article-title":"Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer","volume":"16","author":"Fukui","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtocrr.2022.100353_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/TCRM.S183216","article-title":"Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan","volume":"15","author":"DiBonaventura","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jtocrr.2022.100353_bib14","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2022.100353_bib15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jtocrr.2022.100353_bib16","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cncr.32624","article-title":"Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer","volume":"126","author":"Youn","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2022.100353_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1950411","article-title":"Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study","volume":"10","author":"Morimoto","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtocrr.2022.100353_bib18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtocrr.2022.100353_bib19","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.tibs.2020.03.008","article-title":"Senescent cells: emerging targets for human aging and age-related diseases","volume":"45","author":"Song","year":"2020","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.jtocrr.2022.100353_bib20","unstructured":"European Medicines Agency Tecentriq https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/tecentriq-h-c-004143-ii-0018-epar-assessment-report-variation_en.pdf. Accessed June 20, 2022."},{"key":"10.1016\/j.jtocrr.2022.100353_bib21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/1759-7714.12381","article-title":"Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer","volume":"7","author":"Imai","year":"2016","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtocrr.2022.100353_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jgo.2018.10.001","article-title":"The effect of age on referral to an oncologist and receipt of chemotherapy among small cell lung cancer patients in Ontario, Canada","volume":"10","author":"Doherty","year":"2019","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.jtocrr.2022.100353_bib23","article-title":"A\u00a0real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with extensive-stage SCLC in Canada","volume":"2","author":"Elegbede","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2022.100353_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3816\/CLC.2006.n.041","article-title":"Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status","volume":"8","author":"Lilenbaum","year":"2006","journal-title":"Clin Lung Cancer"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322000777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322000777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:37:44Z","timestamp":1762987064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364322000777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2666364322000777"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100353","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100353"}}